Point-of-Care Diagnostics to Grow From $20.6B to $31.5B by 2031
Analysis
A market forecast puts point-of-care diagnostics at $20.63B in 2026, rising to $31.46B by 2031, a trajectory that implies high-single-digit annual growth in a category the healthcare system has been moving toward for a decade. The player set is wide, spanning QDEL, 6869.T, ROP.SW, SHL.DE, ABT, DHR and TRIB among the names profiled. Why it matters: point of care is a distribution shift, moving testing from central laboratories to the point of decision. Suppliers whose platforms fit clinic, emergency and ambulatory settings capture a structurally larger pool. The 2031 number matters less than the mix, because the equity case depends on which platform converts the category growth into volume first. The forecast is a market-size exercise rather than a competitive map, and it profiles a long list of participants. The read-through for investors across this ticker set is that the category is growing, but the premium still belongs to the platform with the clearest route to volume in the fast-moving segments.
Highlights
- The category is forecast to expand from $20.6B to $31.5B over five years
- Point of care is a structural shift in how diagnostics are delivered
Lowlights
- Sizing forecasts do not allocate the growth among competitors
- Heavy player fragmentation can cap pricing power
Bull News
- A multi-billion-dollar category tailwind favors platform players
- The move away from central labs supports demand for rapid tests
Bear News
- Fragmented competition pushes pressure on price and access
- Growth is forecast, not contracted, for any single name
Point-of-care diagnostics remains one of the cleaner secular pools in the laboratory world, with $31.46B by 2031 as a reasonable anchor. The question across QDEL, 6869.T, ROP.SW, SHL.DE, ABT, DHR and TRIB is not whether the category grows but who captures the incremental share. The multiple expansion will follow the platform that proves volume conversion, not the market-size report itself.